Daily Anesthesiology Research Analysis
Analyzed 110 papers and selected 3 impactful papers.
Summary
Three anesthesia-focused studies stand out today: a randomized trial shows hypoxic preconditioning improves intraoperative oxygenation and postoperative recovery in children undergoing thoracoscopic lung surgery; another randomized trial finds dexmedetomidine via nasal spray reduces hypoxemia during ERCP with convenience comparable to intravenous use; and a nationwide cohort comparing TIVA versus inhalational anesthesia for one-lung ventilation finds no mortality difference but distinct, clinically meaningful complication profiles.
Research Themes
- Pediatric perioperative lung protection strategies
- Sedation route innovation and hypoxemia mitigation
- Anesthetic technique choice and thoracic surgery outcomes
Selected Articles
1. Hypoxic preconditioning improves intraoperative oxygenation and postoperative recovery in children undergoing thoracoscopic surgery: a randomized controlled trial.
In a single-center randomized 2×2 factorial trial of pediatric thoracoscopic lung surgery, hypoxic preconditioning improved oxygenation during one-lung ventilation and enhanced postoperative recovery compared with no preconditioning. The findings support HPC as a feasible and effective intraoperative lung-protective maneuver in children.
Impact: This RCT provides prospective evidence for a simple, intraoperative intervention that improves oxygenation and recovery in a vulnerable pediatric population undergoing one-lung ventilation.
Clinical Implications: Consider incorporating hypoxic preconditioning cycles during pediatric thoracoscopic procedures requiring one-lung ventilation to improve oxygenation and recovery, with protocolized monitoring to ensure safety.
Key Findings
- Hypoxic preconditioning significantly improved intraoperative oxygenation (higher PaO2/FiO2 at 30 minutes of one-lung ventilation) versus control.
- Postoperative recovery was enhanced in the HPC group compared with no preconditioning.
- A 2×2 factorial design demonstrated feasibility of delivering HPC (and RIPC) protocols in pediatric thoracoscopic anesthesia.
Methodological Strengths
- Randomized, factorial (2×2) controlled design with protocolized interventions
- Prospectively registered clinical trial with predefined primary outcome
Limitations
- Single-center study may limit generalizability
- Incomplete reporting of some numerical outcomes in abstract; long-term outcomes not assessed
Future Directions: Multicenter trials with standardized HPC protocols should evaluate safety, optimal dosing (cycles/duration), and effects on postoperative pulmonary complications and length of stay.
BACKGROUND: Hypoxia preconditioning (HPC) and remote ischemic preconditioning (RIPC) are potential lung-protective strategies, but their efficacy in pediatric thoracic surgery remains unclear. This randomized controlled trial aimed to evaluate the effects of HPC, alone or in combination with RIPC, in children undergoing video-assisted thoracoscopic pulmonary resection. METHODS: In a single-center, 2 × 2 factorial randomized trial, 160 children (<18 years) undergoing thoracoscopic lung surgery were allocated to four groups: Control (no preconditioning), HPC (three cycles of 5-min hypoxia/ventilation in the non-dependent lung), RIPC (three cycles of 5-min limb ischemia/reperfusion), and combined HPC + RIPC. The primary outcome was the PaO RESULTS: A total of 139 patients were included in the final analysis. Compared with the control group, HPC significantly improved oxygenation at 30 min of OLV (PaO CONCLUSION: HPC was associated with improved intraoperative oxygenation and enhanced postoperative recovery in children undergoing thoracoscopic pulmonary surgery. These findings suggest that HPC may represent a simple and promising lung-protective strategy in pediatric thoracic anesthesia. CLINICAL TRIAL REGISTRATION: Identifier ChiCTR2000038658, https://www.chictr.org.cn/showproj.html?proj=61845.
2. Effects of dexmedetomidine nasal spray combined with propofol for deep sedation in patients undergoing endoscopic retrograde cholangiopancreatography: a prospective randomized study.
In 180 adults undergoing ERCP, adding dexmedetomidine reduced intraoperative hypoxemia versus propofol-only control, whether delivered by nasal spray or intravenously. The intranasal route offered comparable safety and efficacy to IV with shorter anesthesia duration and greater convenience.
Impact: Demonstrates a practical, non-invasive route for dexmedetomidine that reduces hypoxemia during a high-risk endoscopic procedure, potentially simplifying workflow and improving safety.
Clinical Implications: Intranasal dexmedetomidine premedication can be considered to reduce hypoxemia during ERCP deep sedation and may streamline pre-procedure preparation without IV loading.
Key Findings
- Intraoperative hypoxemia was significantly lower with dexmedetomidine (nasal spray or IV) versus control (5.0% vs 21.7%).
- Propofol consumption and anesthesia duration were reduced with dexmedetomidine coadministration.
- Intranasal dexmedetomidine achieved efficacy and safety comparable to intravenous infusion while offering greater procedural convenience.
Methodological Strengths
- Prospective randomized design with an active comparator and control
- Pre-registered clinical trial with clear primary and secondary outcomes
Limitations
- Single-center trial may limit external validity
- Blinding to route of administration is inherently challenging, introducing potential performance bias
Future Directions: Confirm findings in multicenter settings, explore dosing optimization for intranasal delivery, and evaluate applicability to other endoscopic procedures and high-risk patients.
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) requires effective and safe deep sedation. Dexmedetomidine is a promising sedative in painless procedures. This study investigated the efficacy and safety of preoperative dexmedetomidine via nasal spray and conventional intravenous infusion for ERCP deep sedation. METHODS: In this single-center, prospective randomized trial, 180 adult patients scheduled for ERCP were assigned to three groups: preoperative nasal spray (Group NS), intravenous pumping (Group IP), or control without dexmedetomidine (Group C). A propofol-based protocol was applied to all groups. Primary outcome was the incidence of intraoperative hypoxemia. Secondary outcomes included propofol consumption, hemodynamic stability, recovery profiles, and the incidence of other adverse events. RESULTS: Compared to Group C, both Group NS and Group IP significantly reduced intraoperative hypoxemia (5.0% vs. 5.0% vs. 21.7%, CONCLUSION: Dexmedetomidine nasal spray combined with propofol is as effective and safe as the intravenous route for ERCP deep sedation, offering the additional advantages of shorter anesthesia duration and greater procedural convenience. CLINICAL TRIAL REGISTRATION: https://register.clinicaltrials.gov, identifier NCT07204106.
3. Association of anesthetic technique with mortality and morbidity in patients undergoing surgery with one-lung ventilation under general anaesthesia.
In a national propensity-matched cohort of 22,925 OLV cases, TIVA and inhalational anesthesia had similar 90-day and 1-year mortality. Notably, TIVA was associated with more sepsis, acute coronary events, AKI, and heart failure, but less pneumonia, pulmonary embolism, and wound infection, underscoring the need for individualized anesthetic selection.
Impact: Provides large-scale, real-world evidence clarifying that mortality may not differ by anesthetic modality in OLV, while revealing divergent complication profiles that can inform risk-tailored anesthetic planning.
Clinical Implications: When planning anesthesia for OLV, mortality should not drive selection alone; instead, align anesthetic choice with patient-specific risks (e.g., infection vs. cardiorenal events) and surgical priorities.
Key Findings
- After 1:1 propensity matching (n=6,811 per group), 90-day mortality did not differ between TIVA and inhalational anesthesia (OR 1.08; 95% CI 0.91–1.28; P=0.37).
- One-year all-cause mortality was similar between groups (HR 1.07; 95% CI 0.96–1.19; P=0.21).
- TIVA showed higher rates of sepsis, acute coronary events, AKI, and heart failure, but lower rates of postoperative pneumonia, pulmonary embolism, and wound infection compared to inhalational anesthesia.
Methodological Strengths
- Large, nationwide cohort with robust 1:1 propensity score matching
- Multiple clinically relevant endpoints (90-day and 1-year mortality; detailed complication profiles)
Limitations
- Observational design subject to residual confounding despite matching
- Single-year dataset (2021) may limit temporal generalizability
Future Directions: Prospective comparative effectiveness studies should examine causal pathways for complication differences and evaluate protocolized strategies to mitigate risk profiles associated with each anesthetic technique.
BACKGROUND: General anesthesia is the standard requirement for surgical procedures necessitating one-lung ventilation (OLV). The choice of anesthesia is a critical consideration, but which anesthetic modality is the most advantageous remains controversial. We evaluated the association of propofol-based total intravenous anesthesia (TIVA) and inhalation anesthesia (INH) during OLV with mortality and morbidity. METHODS: This population-based cohort study included adult patients who underwent OLV for surgery between January 1 and December 31, 2021, in South Korea. The INH and TIVA groups underwent 1:1 propensity score matching to balance patient characteristics before group comparisons. The endpoints were 90-day mortality, 1-year all-cause mortality, and postoperative complications. RESULTS: The final study included 22,925 patients who underwent surgery with OLV under general anaesthesia. The INH and TIVA groups included 16,114 and 6,811 patients, respectively. After propensity score matching, data of 6,811 patients per group were compared. Logistic regression analysis revealed no statistically significant difference in the 90-day mortality rate between the two groups [odds ratio (OR) 1.08; 95% confidence interval (CI): 0.91-1.28; P=0.37]. Moreover, the 1-year all-cause mortality rate did not differ significantly between the groups in Cox regression analysis (hazard ratio 1.07; 95% CI: 0.96-1.19; P=0.21). However, TIVA was associated with higher rates of sepsis, acute coronary events, acute kidney injury, and heart failure, whereas it was associated with lower rates of postoperative pneumonia, pulmonary embolism, and wound infection compared to the INH group. CONCLUSIONS: The type of anesthesia used during surgery with OLV was not significantly associated with 90-day or 1-year all-cause mortality. However, the choice of anesthetic agent appears to influence specific postoperative complication profiles, suggesting the need for an individualized approach based on patient-specific risk factors.